Prognostic	B:C1514474
factors	I:C1514474
in	O
patients	O
with	O
spinal	O
metastasis	I:C0347016
:	O
a	O
systematic	O
review	I:C1955832
and	O
meta-analysis	O
.	O

Prognostic	O
factors	I:C1514474
in	O
patients	O
with	O
spinal	B:C0347016
metastasis	I:C0347016
:	O
a	O
systematic	O
review	I:C1955832
and	O
meta-analysis	O
.	O

Prognostic	O
factors	I:C1514474
in	O
patients	O
with	O
spinal	O
metastasis	I:C0347016
:	O
a	O
systematic	B:C1955832
review	I:C1955832
and	O
meta-analysis	O
.	O

Prognostic	O
factors	I:C1514474
in	O
patients	O
with	O
spinal	O
metastasis	I:C0347016
:	O
a	O
systematic	O
review	I:C1955832
and	O
meta-analysis	B:C0920317
.	O

Incidence	O
of	O
symptomatic	O
spinal	B:C0347016
metastasis	I:C0347016
has	O
increased	O
owing	O
to	O
improvement	O
in	O
treatment	O
of	O
the	O
disease	O
.	O

Incidence	O
of	O
symptomatic	O
spinal	O
metastasis	I:C0347016
has	O
increased	O
owing	O
to	O
improvement	O
in	O
treatment	O
of	O
the	O
disease	B:C0012634
.	O

One	O
of	O
the	O
key	O
factors	O
that	O
influences	O
decision	B:C0011109
-	I:C0011109
making	I:C0011109
is	O
expected	O
patient	O
survival	O
.	O

To	O
our	O
knowledge	O
,	O
no	O
systematic	B:C1955832
reviews	I:C1955832
or	O
meta-	O
analysis	I:C0920317
have	O
been	O
conducted	O
that	O
review	O
independent	O
prognostic	O
factors	I:C1514474
in	O
spinal	O
metastases	I:C0347016
.	O

To	O
our	O
knowledge	O
,	O
no	O
systematic	O
reviews	I:C1955832
or	O
meta-	B:C0920317
analysis	I:C0920317
have	O
been	O
conducted	O
that	O
review	O
independent	O
prognostic	O
factors	I:C1514474
in	O
spinal	O
metastases	I:C0347016
.	O

To	O
our	O
knowledge	O
,	O
no	O
systematic	O
reviews	I:C1955832
or	O
meta-	O
analysis	I:C0920317
have	O
been	O
conducted	O
that	O
review	O
independent	O
prognostic	B:C1514474
factors	I:C1514474
in	O
spinal	O
metastases	I:C0347016
.	O

To	O
our	O
knowledge	O
,	O
no	O
systematic	O
reviews	I:C1955832
or	O
meta-	O
analysis	I:C0920317
have	O
been	O
conducted	O
that	O
review	O
independent	O
prognostic	O
factors	I:C1514474
in	O
spinal	B:C0347016
metastases	I:C0347016
.	O

This	O
study	B:C0008972
aimed	O
to	O
determine	O
independent	O
prognostic	O
factors	I:C1514474
that	O
affect	O
outcome	O
in	O
patients	O
with	O
metastatic	O
spine	I:C0347016
disease	I:C0347016
.	O

This	O
study	O
aimed	O
to	O
determine	O
independent	O
prognostic	B:C1514474
factors	I:C1514474
that	O
affect	O
outcome	O
in	O
patients	O
with	O
metastatic	O
spine	I:C0347016
disease	I:C0347016
.	O

This	O
study	O
aimed	O
to	O
determine	O
independent	O
prognostic	O
factors	I:C1514474
that	O
affect	O
outcome	O
in	O
patients	O
with	O
metastatic	B:C0347016
spine	I:C0347016
disease	I:C0347016
.	O

This	O
is	O
a	O
systematic	O
literature	B:C0282441
review	I:C0282441
and	O
meta-	O
analysis	I:C0920317
of	O
publications	O
for	O
prognostic	O
factors	I:C1514474
in	O
spinal	O
metastatic	I:C0347016
disease	I:C0347016
.	O

This	O
is	O
a	O
systematic	O
literature	O
review	I:C0282441
and	O
meta-	B:C0920317
analysis	I:C0920317
of	O
publications	O
for	O
prognostic	O
factors	I:C1514474
in	O
spinal	O
metastatic	I:C0347016
disease	I:C0347016
.	O

This	O
is	O
a	O
systematic	O
literature	O
review	I:C0282441
and	O
meta-	O
analysis	I:C0920317
of	O
publications	O
for	O
prognostic	B:C1514474
factors	I:C1514474
in	O
spinal	O
metastatic	I:C0347016
disease	I:C0347016
.	O

This	O
is	O
a	O
systematic	O
literature	O
review	I:C0282441
and	O
meta-	O
analysis	I:C0920317
of	O
publications	O
for	O
prognostic	O
factors	I:C1514474
in	O
spinal	B:C0347016
metastatic	I:C0347016
disease	I:C0347016
.	O

Pooled	O
patient	O
results	O
from	O
cohort	O
and	O
observational	B:C1518527
studies	I:C1518527
.	O

Meta	B:C0920317
-analysis	I:C0920317
for	O
poor	O
prognostic	O
factors	I:C1514474
as	O
determined	O
by	O
hazard	O
ratio	O
(	O
HR	O
)	O
and	O
95	O
%	O
confidential	O
interval	O
(	O
95	O
%	O
CI	O
)	O
.	O

Meta	O
-analysis	I:C0920317
for	O
poor	O
prognostic	B:C1514474
factors	I:C1514474
as	O
determined	O
by	O
hazard	O
ratio	O
(	O
HR	O
)	O
and	O
95	O
%	O
confidential	O
interval	O
(	O
95	O
%	O
CI	O
)	O
.	O

We	O
systematically	O
searched	O
relevant	O
publications	B:C0034036
in	O
PubMed	O
and	O
Embase	O
.	O

We	O
systematically	O
searched	O
relevant	O
publications	O
in	O
PubMed	B:C1138432
and	O
Embase	O
.	O

We	O
systematically	O
searched	O
relevant	O
publications	O
in	O
PubMed	O
and	O
Embase	B:C0282574
.	O

The	O
following	O
search	O
terms	O
were	O
used	O
:	O
(	O
"	O
'	O
spinal	B:C0347016
metastases	I:C0347016
'	O
"	O
OR	O
"	O
'	O
vertebral	O
metastases	I:C0347016
'"	O
OR	O
"	O
spinal	O
metastasis	I:C0347016
"	O
OR	O
'	O
vertebral	O
metastases	I:C0347016
')	O
AND	O
(	O
'	O
"	O
prognostic	O
factors	I:C1514474
"	O
'	O
OR	O
"	O
'	O
survival	O
'	O
"	O
)	O
.	O

The	O
following	O
search	O
terms	O
were	O
used	O
:	O
(	O
"	O
'	O
spinal	O
metastases	I:C0347016
'	O
"	O
OR	O
"	O
'	O
vertebral	B:C0347016
metastases	I:C0347016
'"	O
OR	O
"	O
spinal	O
metastasis	I:C0347016
"	O
OR	O
'	O
vertebral	O
metastases	I:C0347016
')	O
AND	O
(	O
'	O
"	O
prognostic	O
factors	I:C1514474
"	O
'	O
OR	O
"	O
'	O
survival	O
'	O
"	O
)	O
.	O

The	O
following	O
search	O
terms	O
were	O
used	O
:	O
(	O
"	O
'	O
spinal	O
metastases	I:C0347016
'	O
"	O
OR	O
"	O
'	O
vertebral	O
metastases	I:C0347016
'"	O
OR	O
"	O
spinal	B:C0347016
metastasis	I:C0347016
"	O
OR	O
'	O
vertebral	O
metastases	I:C0347016
')	O
AND	O
(	O
'	O
"	O
prognostic	O
factors	I:C1514474
"	O
'	O
OR	O
"	O
'	O
survival	O
'	O
"	O
)	O
.	O

The	O
following	O
search	O
terms	O
were	O
used	O
:	O
(	O
"	O
'	O
spinal	O
metastases	I:C0347016
'	O
"	O
OR	O
"	O
'	O
vertebral	O
metastases	I:C0347016
'"	O
OR	O
"	O
spinal	O
metastasis	I:C0347016
"	O
OR	O
'	O
vertebral	B:C0347016
metastases	I:C0347016
')	O
AND	O
(	O
'	O
"	O
prognostic	O
factors	I:C1514474
"	O
'	O
OR	O
"	O
'	O
survival	O
'	O
"	O
)	O
.	O

The	O
following	O
search	O
terms	O
were	O
used	O
:	O
(	O
"	O
'	O
spinal	O
metastases	I:C0347016
'	O
"	O
OR	O
"	O
'	O
vertebral	O
metastases	I:C0347016
'"	O
OR	O
"	O
spinal	O
metastasis	I:C0347016
"	O
OR	O
'	O
vertebral	O
metastases	I:C0347016
')	O
AND	O
(	O
'	O
"	O
prognostic	B:C1514474
factors	I:C1514474
"	O
'	O
OR	O
"	O
'	O
survival	O
'	O
"	O
)	O
.	O

Inclusion	O
criteria	O
were	O
prospective	O
and	O
retrospective	O
cohort	O
series	O
that	O
report	O
HR	O
and	O
95	O
%	O
CI	O
of	O
independent	O
prognostic	B:C1514474
factors	I:C1514474
from	O
multivariate	O
analysis	O
.	O

Two	O
reviewers	B:C1882950
independently	O
assessed	O
all	O
papers	O
.	O

The	O
quality	O
of	O
included	O
papers	O
was	O
assessed	O
by	O
using	O
Newcastle	B:C0282574
-	I:C0282574
Ottawa	I:C0282574
Scale	I:C0282574
for	O
cohort	O
studies	O
and	O
publication	O
bias	O
was	O
assessed	O
by	O
using	O
funnel	O
plot	I:C0237913
,	O
Begg	O
test	I:C0237913
,	O
and	O
Egger	O
test	I:C0237913
.	O

The	O
quality	O
of	O
included	O
papers	O
was	O
assessed	O
by	O
using	O
Newcastle	O
-	I:C0282574
Ottawa	I:C0282574
Scale	I:C0282574
for	O
cohort	O
studies	O
and	O
publication	B:C0034036
bias	O
was	O
assessed	O
by	O
using	O
funnel	O
plot	I:C0237913
,	O
Begg	O
test	I:C0237913
,	O
and	O
Egger	O
test	I:C0237913
.	O

The	O
quality	O
of	O
included	O
papers	O
was	O
assessed	O
by	O
using	O
Newcastle	O
-	I:C0282574
Ottawa	I:C0282574
Scale	I:C0282574
for	O
cohort	O
studies	O
and	O
publication	O
bias	O
was	O
assessed	O
by	O
using	O
funnel	B:C0237913
plot	I:C0237913
,	O
Begg	O
test	I:C0237913
,	O
and	O
Egger	O
test	I:C0237913
.	O

The	O
quality	O
of	O
included	O
papers	O
was	O
assessed	O
by	O
using	O
Newcastle	O
-	I:C0282574
Ottawa	I:C0282574
Scale	I:C0282574
for	O
cohort	O
studies	O
and	O
publication	O
bias	O
was	O
assessed	O
by	O
using	O
funnel	O
plot	I:C0237913
,	O
Begg	B:C0237913
test	I:C0237913
,	O
and	O
Egger	O
test	I:C0237913
.	O

The	O
quality	O
of	O
included	O
papers	O
was	O
assessed	O
by	O
using	O
Newcastle	O
-	I:C0282574
Ottawa	I:C0282574
Scale	I:C0282574
for	O
cohort	O
studies	O
and	O
publication	O
bias	O
was	O
assessed	O
by	O
using	O
funnel	O
plot	I:C0237913
,	O
Begg	O
test	I:C0237913
,	O
and	O
Egger	B:C0237913
test	I:C0237913
.	O

The	O
prognostic	B:C1514474
factors	I:C1514474
that	O
were	O
mentioned	O
in	O
at	O
least	O
three	O
publications	O
were	O
pooled	O
.	O

The	O
prognostic	O
factors	I:C1514474
that	O
were	O
mentioned	O
in	O
at	O
least	O
three	O
publications	B:C0034036
were	O
pooled	O
.	O

Meta	B:C0920317
-analysis	I:C0920317
was	O
performed	O
using	O
HR	O
and	O
95	O
%	O
CI	O
as	O
the	O
primary	O
outcomes	O
of	O
interest	O
.	O

Heterogeneity	O
was	O
assessed	O
using	O
the	O
I	B:C0242481
(	I:C0242481
2	I:C0242481
)	I:C0242481
method	I:C0242481
.	O

A	O
total	O
of	O
3,959	O
abstracts	B:C0600678
(	O
1,382	O
from	O
PubMed	O
and	O
2,577	O
from	O
Embase	O
)	O
were	O
identified	O
through	O
database	O
search	O
and	O
40	O
publications	O
were	O
identified	O
through	O
review	O
of	O
cited	O
publications	O
.	O

A	O
total	O
of	O
3,959	O
abstracts	O
(	O
1,382	O
from	O
PubMed	B:C1138432
and	O
2,577	O
from	O
Embase	O
)	O
were	O
identified	O
through	O
database	O
search	O
and	O
40	O
publications	O
were	O
identified	O
through	O
review	O
of	O
cited	O
publications	O
.	O

A	O
total	O
of	O
3,959	O
abstracts	O
(	O
1,382	O
from	O
PubMed	O
and	O
2,577	O
from	O
Embase	B:C0282574
)	O
were	O
identified	O
through	O
database	O
search	O
and	O
40	O
publications	O
were	O
identified	O
through	O
review	O
of	O
cited	O
publications	O
.	O

A	O
total	O
of	O
3,959	O
abstracts	O
(	O
1,382	O
from	O
PubMed	O
and	O
2,577	O
from	O
Embase	O
)	O
were	O
identified	O
through	O
database	B:C0242356
search	O
and	O
40	O
publications	O
were	O
identified	O
through	O
review	O
of	O
cited	O
publications	O
.	O

A	O
total	O
of	O
3,959	O
abstracts	O
(	O
1,382	O
from	O
PubMed	O
and	O
2,577	O
from	O
Embase	O
)	O
were	O
identified	O
through	O
database	O
search	O
and	O
40	O
publications	B:C0034036
were	O
identified	O
through	O
review	O
of	O
cited	O
publications	O
.	O

A	O
total	O
of	O
3,959	O
abstracts	O
(	O
1,382	O
from	O
PubMed	O
and	O
2,577	O
from	O
Embase	O
)	O
were	O
identified	O
through	O
database	O
search	O
and	O
40	O
publications	O
were	O
identified	O
through	O
review	O
of	O
cited	O
publications	B:C0034036
.	O

The	O
reviewers	B:C1882950
selected	O
a	O
total	O
of	O
51	O
studies	O
for	O
qualitative	O
synthesis	O
and	O
43	O
studies	O
for	O
meta-	O
analysis	I:C0920317
.	O

The	O
reviewers	O
selected	O
a	O
total	O
of	O
51	O
studies	O
for	O
qualitative	O
synthesis	O
and	O
43	O
studies	O
for	O
meta-	B:C0920317
analysis	I:C0920317
.	O

Seventeen	O
poor	O
prognostic	B:C1514474
factors	I:C1514474
were	O
identified	O
.	O

These	O
included	O
presence	B:C0150312
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	B:C0521654
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	B:C1274039
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	B:C0560046
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	B:C0085203
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	B:C0085203
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	B:C0560046
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	B:C1274039
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	B:C0150312
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	B:C0153690
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	B:C0150312
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	B:C0153690
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	B:C1515974
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	B:C0150312
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	B:C1515974
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	B:C0243107
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	B:C0521654
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	B:C0085203
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	B:C0243107
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	B:C0521654
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	B:C0085203
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	B:C0920688
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	B:C0085203
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	B:C0282574
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	B:C0282574
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	B:C0282574
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	B:C0282574
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	B:C1512162
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	B:C1512162
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	B:C0441800
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	B:C0150312
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	B:C0442045
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	B:C0027627
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	B:C0018270
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	B:C0027651
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	B:C0282574
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	B:C0018270
tumor	O
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	B:C0027651
on	O
TS	O
classification	I:C0282574
.	O

These	O
included	O
presence	O
of	O
a	O
neurologic	O
deficit	I:C0521654
before	O
surgery	O
,	O
non-ambulatory	O
status	O
before	O
radiotherapy	O
(	O
radiotherapy	O
)	O
,	O
non-ambulatory	O
status	O
before	O
surgery	O
,	O
presence	O
of	O
bone	O
metastases	I:C0153690
,	O
presence	O
of	O
multiple	O
bone	O
metastases	I:C0153690
(	O
>	O
2	O
sites	O
)	O
,	O
presence	O
of	O
multiple	O
spinal	O
metastases	O
(	O
>	O
3	O
sites	O
)	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
7	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
development	O
of	O
motor	O
deficit	I:C0521654
in	O
<	O
14	O
days	O
before	O
initiating	O
radiotherapy	O
,	O
time	O
interval	O
from	O
cancer	O
diagnosis	I:C0920688
to	O
radiotherapy	O
<	O
15	O
months	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
(	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
)	O
10	O
-	O
40	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
50	O
-	O
70	O
,	O
Karnofsky	O
Performance	I:C0282574
Score	I:C0282574
<	O
70	O
,	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
(	O
Eastern	O
Cooperative	I:C1512162
Oncology	I:C1512162
Group	I:C1512162
)	O
grade	O
3	I:C0441800
-	I:C0441800
4	I:C0441800
,	O
male	O
gender	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
moderate	O
growth	O
tumor	O
on	O
Tomita	O
score	I:C0282574
(	I:C0282574
TS	I:C0282574
)	I:C0282574
classification	I:C0282574
,	O
and	O
rapid	O
growth	O
tumor	O
on	O
TS	B:C0282574
classification	I:C0282574
.	O

Seventeen	O
independent	O
poor	O
prognostic	B:C1514474
factors	I:C1514474
were	O
identified	O
in	O
this	O
study	O
.	O

Seventeen	O
independent	O
poor	O
prognostic	O
factors	I:C1514474
were	O
identified	O
in	O
this	O
study	B:C0008972
.	O

These	O
can	O
be	O
categorized	O
into	O
cancer	B:C0006826
-	O
specific	O
and	O
nonspecific	O
prognostic	O
factors	I:C1514474
.	O

These	O
can	O
be	O
categorized	O
into	O
cancer	O
-	O
specific	O
and	O
nonspecific	O
prognostic	B:C1514474
factors	I:C1514474
.	O

A	O
tumor	B:C0027651
-	O
based	O
prognostic	O
scoring	I:C0282574
system	I:C0282574
that	O
combines	O
all	O
specific	O
and	O
general	O
factors	O
may	O
enhance	O
the	O
accuracy	O
of	O
survival	O
prediction	O
in	O
patients	O
with	O
metastatic	O
spine	I:C0347016
disease	I:C0347016
.	O

A	O
tumor	O
-	O
based	O
prognostic	B:C0282574
scoring	I:C0282574
system	I:C0282574
that	O
combines	O
all	O
specific	O
and	O
general	O
factors	O
may	O
enhance	O
the	O
accuracy	O
of	O
survival	O
prediction	O
in	O
patients	O
with	O
metastatic	O
spine	I:C0347016
disease	I:C0347016
.	O

A	O
tumor	O
-	O
based	O
prognostic	O
scoring	I:C0282574
system	I:C0282574
that	O
combines	O
all	O
specific	O
and	O
general	O
factors	O
may	O
enhance	O
the	O
accuracy	O
of	O
survival	O
prediction	O
in	O
patients	O
with	O
metastatic	B:C0347016
spine	I:C0347016
disease	I:C0347016
.	O

